rwj-333369 has been researched along with Essential-Tremor* in 1 studies
1 trial(s) available for rwj-333369 and Essential-Tremor
Article | Year |
---|---|
Carisbamate in essential tremor: brief report of a proof of concept study.
The efficacy and safety of carisbamate, an investigational neuromodulator currently in development for epilepsy, were examined in a multicenter, randomized, double-blind, cross-over, placebo-controlled study of essential tremor. Sixty-two patients (intent-to-treat analysis set; mean age 64 years; 66% men) received carisbamate 400 mg/day or matching placebo in a crossover study design with two 21-day treatment periods. The Fahn-Tolosa-MarĂn Tremor Rating Scale (TRS) was the primary assessment tool. Carisbamate and placebo treatment did not differ in their effect on the TRS (P = 0.94) or on measures of affect, mood, or quality of life. Carisbamate was generally well tolerated and had an adverse event profile comparable to that of placebo. Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticonvulsants; Carbamates; Cross-Over Studies; Double-Blind Method; Essential Tremor; Female; Humans; Male; Middle Aged; Severity of Illness Index; Young Adult | 2010 |